News headlines about Mallinckrodt (NYSE:MNK) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mallinckrodt earned a daily sentiment score of 0.11 on Accern’s scale. Accern also gave headlines about the company an impact score of 44.4577706024664 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
A number of research firms have commented on MNK. UBS downgraded shares of Mallinckrodt from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $70.00 to $24.00 in a research note on Sunday, November 26th. Oppenheimer reiterated a “market perform” rating on shares of Mallinckrodt in a research note on Wednesday, November 22nd. Canaccord Genuity set a $24.00 price objective on shares of Mallinckrodt and gave the company a “hold” rating in a research note on Tuesday, November 14th. Stifel Nicolaus reduced their price objective on shares of Mallinckrodt from $70.00 to $50.00 and set a “buy” rating on the stock in a research note on Wednesday, November 8th. Finally, Morgan Stanley dropped their target price on shares of Mallinckrodt from $40.00 to $27.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 8th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $48.14.
Mallinckrodt (NYSE:MNK) traded down $0.23 during trading on Wednesday, reaching $21.73. 2,859,200 shares of the company’s stock traded hands, compared to its average volume of 2,584,930. Mallinckrodt has a 52-week low of $19.00 and a 52-week high of $55.32. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.05 and a current ratio of 1.38. The firm has a market cap of $2,086.31, a PE ratio of 2.96, a price-to-earnings-growth ratio of 0.40 and a beta of 1.30.
Mallinckrodt (NYSE:MNK) last posted its quarterly earnings data on Tuesday, November 7th. The company reported $1.97 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.80 by $0.17. Mallinckrodt had a net margin of 11.43% and a return on equity of 14.79%. The company had revenue of $793.90 million during the quarter, compared to analyst estimates of $808.93 million. During the same quarter last year, the firm posted $2.04 EPS. The business’s revenue for the quarter was down 10.5% on a year-over-year basis. equities research analysts anticipate that Mallinckrodt will post 7.2 earnings per share for the current year.
In other news, VP Steven J. Romano bought 2,000 shares of the firm’s stock in a transaction on Monday, November 13th. The stock was bought at an average cost of $21.96 per share, for a total transaction of $43,920.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Dr Kneeland Youngblood bought 4,560 shares of the firm’s stock in a transaction on Tuesday, November 28th. The stock was purchased at an average price of $21.94 per share, with a total value of $100,046.40. Following the completion of the acquisition, the director now owns 19,789 shares of the company’s stock, valued at $434,170.66. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 30,460 shares of company stock valued at $659,486. Insiders own 0.53% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://ledgergazette.com/2017/12/06/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-mallinckrodt-plc-mnk-share-price.html.
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with MarketBeat.com's FREE daily email newsletter.